Contact
searchSearch
HMP Global

Respiratory Syncytial Virus

Featured Article

News
Long-Term Effectiveness of RSV Vaccine Declines Over Two Seasons, VHA Study Finds
11/25/2025
Grace Taylor, MS, MA
A large US Veterans Health Administration (VHA) study shows that respiratory syncytial virus (RSV) vaccine protection in older adults remains strong initially but declines substantially over 18 months, especially among immunocompromised...
A large US Veterans Health Administration (VHA) study shows that respiratory syncytial virus (RSV) vaccine protection in older adults remains strong initially but declines substantially over 18 months, especially among immunocompromised...
A large US Veterans Health...
11/25/2025
Pharmacy Learning Network
News
RSV Vaccination Rates Remain Low Among US Veterans
11/19/2025
Grace Taylor, MS, MA
Respiratory syncytial virus (RSV) vaccination rates among US veterans remain low, exposing persistent gaps in preventive care despite widespread eligibility and no-cost access through the Veterans Health Administration (VHA), according to a...
Respiratory syncytial virus (RSV) vaccination rates among US veterans remain low, exposing persistent gaps in preventive care despite widespread eligibility and no-cost access through the Veterans Health Administration (VHA), according to a...
Respiratory syncytial virus...
11/19/2025
Pharmacy Learning Network
News
RSVpreF Vaccine Shows Strong Safety Profile in Adults, Global Analysis Finds
11/14/2025
Grace Taylor, MS, MA
A large global analysis finds bivalent RSVpreF vaccine safe and well tolerated in adults, reinforcing its role in protecting against respiratory syncytial virus infection.
A large global analysis finds bivalent RSVpreF vaccine safe and well tolerated in adults, reinforcing its role in protecting against respiratory syncytial virus infection.
A large global analysis finds...
11/14/2025
Pharmacy Learning Network
News
Primary Care Providers Drive RSV Vaccine Uptake Among Older Adults
11/12/2025
Grace Taylor, MS, MA
A prospective multisite survey study reveals that primary care providers are the leading influence driving older adults to receive the respiratory syncytial virus (RSV) vaccine, highlighting a key opportunity for pharmacists to boost...
A prospective multisite survey study reveals that primary care providers are the leading influence driving older adults to receive the respiratory syncytial virus (RSV) vaccine, highlighting a key opportunity for pharmacists to boost...
A prospective multisite survey...
11/12/2025
Pharmacy Learning Network
News
RSV Poses Significant Threat to Patients With Systemic Autoimmune Rheumatic Diseases
10/31/2025
Grace Taylor, MS, MA
Patients with autoimmune rheumatic diseases face high hospitalization rates from RSV, according to study published in Seminars in Arthritis and Rheumatism.
Patients with autoimmune rheumatic diseases face high hospitalization rates from RSV, according to study published in Seminars in Arthritis and Rheumatism.
Patients with autoimmune...
10/31/2025
Pharmacy Learning Network
News
Dual RSV and Influenza Vaccination Reduces Health Care Utilization and Costs Among Older Adults
10/31/2025
Juliet Gallagher
A new retrospective cohort study using the Humana Healthcare Research database highlights the significant clinical and economic benefits of respiratory syncytial virus (RSV) vaccination among older adults in the US.
A new retrospective cohort study using the Humana Healthcare Research database highlights the significant clinical and economic benefits of respiratory syncytial virus (RSV) vaccination among older adults in the US.
A new retrospective cohort study...
10/31/2025
Pharmacy Learning Network
News
RSVpreF Vaccine Proves Highly Effective Against Severe RSV in Older Adults
10/29/2025
Grace Taylor, MS, MA
A real-world study led by Kaiser Permanente Southern California shows that Pfizer’s RSVpreF vaccine provides strong protection against severe respiratory syncytial virus (RSV)–related illness and hospitalizations in older adults, including...
A real-world study led by Kaiser Permanente Southern California shows that Pfizer’s RSVpreF vaccine provides strong protection against severe respiratory syncytial virus (RSV)–related illness and hospitalizations in older adults, including...
A real-world study led by Kaiser...
10/29/2025
Pharmacy Learning Network
News
RSV Poses Sixfold Higher Hospitalization and Death Risk for Long-Term Care Residents
10/21/2025
Lisa Kuhns, PhD, MD
Older adults living in long-term care facilities face a dramatically higher risk of severe illness and death from respiratory syncytial virus (RSV) than their community-dwelling peers, according to new data published in The Journal of the...
Older adults living in long-term care facilities face a dramatically higher risk of severe illness and death from respiratory syncytial virus (RSV) than their community-dwelling peers, according to new data published in The Journal of the...
Older adults living in long-term...
10/21/2025
Pharmacy Learning Network
News
RSV Vaccines Cut Hospitalizations in Older Adults but Show Gaps in High-Risk Groups
09/29/2025
Grace Taylor, MS, MA
A new 2-season study finds respiratory syncytial virus (RSV) vaccines significantly reduce hospitalizations in adults 60 and older, though protection wanes over time and is weaker in immunocompromised patients and those with cardiovascular...
A new 2-season study finds respiratory syncytial virus (RSV) vaccines significantly reduce hospitalizations in adults 60 and older, though protection wanes over time and is weaker in immunocompromised patients and those with cardiovascular...
A new 2-season study finds...
09/29/2025
Pharmacy Learning Network
News
RSV Pneumonia Leads to Elevated ICU Admissions and Mortality in Older Adults
08/08/2025
Grace Taylor, MS, MA
Respiratory syncytial virus (RSV) pneumonia leads to high intensive care unit (ICU) admission and mortality rates in older adults, rivaling those of influenza and human metapneumovirus, according to a study published in the Journal of...
Respiratory syncytial virus (RSV) pneumonia leads to high intensive care unit (ICU) admission and mortality rates in older adults, rivaling those of influenza and human metapneumovirus, according to a study published in the Journal of...
Respiratory syncytial virus...
08/08/2025
Pharmacy Learning Network
News
Comorbidities Drive ICU Admission and Mortality in RSV and HMPV Among Older Adults
07/16/2025
Grace Taylor, MS, MA
A Colorado study reveals distinct comorbidity-driven risks for ICU admission and mortality in older adults hospitalized with respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).]
A Colorado study reveals distinct comorbidity-driven risks for ICU admission and mortality in older adults hospitalized with respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).]
A Colorado study reveals...
07/16/2025
Pharmacy Learning Network

Newsfeed

News
Long-Term Effectiveness of RSV Vaccine Declines Over Two Seasons, VHA Study Finds
11/25/2025
Grace Taylor, MS, MA
A large US Veterans Health Administration (VHA) study shows that respiratory syncytial virus (RSV) vaccine protection in older adults remains strong initially but declines substantially over 18 months, especially among immunocompromised...
A large US Veterans Health Administration (VHA) study shows that respiratory syncytial virus (RSV) vaccine protection in older adults remains strong initially but declines substantially over 18 months, especially among immunocompromised...
A large US Veterans Health...
11/25/2025
Pharmacy Learning Network
News
RSV Vaccination Rates Remain Low Among US Veterans
11/19/2025
Grace Taylor, MS, MA
Respiratory syncytial virus (RSV) vaccination rates among US veterans remain low, exposing persistent gaps in preventive care despite widespread eligibility and no-cost access through the Veterans Health Administration (VHA), according to a...
Respiratory syncytial virus (RSV) vaccination rates among US veterans remain low, exposing persistent gaps in preventive care despite widespread eligibility and no-cost access through the Veterans Health Administration (VHA), according to a...
Respiratory syncytial virus...
11/19/2025
Pharmacy Learning Network
News
RSVpreF Vaccine Shows Strong Safety Profile in Adults, Global Analysis Finds
11/14/2025
Grace Taylor, MS, MA
A large global analysis finds bivalent RSVpreF vaccine safe and well tolerated in adults, reinforcing its role in protecting against respiratory syncytial virus infection.
A large global analysis finds bivalent RSVpreF vaccine safe and well tolerated in adults, reinforcing its role in protecting against respiratory syncytial virus infection.
A large global analysis finds...
11/14/2025
Pharmacy Learning Network
News
Primary Care Providers Drive RSV Vaccine Uptake Among Older Adults
11/12/2025
Grace Taylor, MS, MA
A prospective multisite survey study reveals that primary care providers are the leading influence driving older adults to receive the respiratory syncytial virus (RSV) vaccine, highlighting a key opportunity for pharmacists to boost...
A prospective multisite survey study reveals that primary care providers are the leading influence driving older adults to receive the respiratory syncytial virus (RSV) vaccine, highlighting a key opportunity for pharmacists to boost...
A prospective multisite survey...
11/12/2025
Pharmacy Learning Network
News
RSV Poses Significant Threat to Patients With Systemic Autoimmune Rheumatic Diseases
10/31/2025
Grace Taylor, MS, MA
Patients with autoimmune rheumatic diseases face high hospitalization rates from RSV, according to study published in Seminars in Arthritis and Rheumatism.
Patients with autoimmune rheumatic diseases face high hospitalization rates from RSV, according to study published in Seminars in Arthritis and Rheumatism.
Patients with autoimmune...
10/31/2025
Pharmacy Learning Network
News
Dual RSV and Influenza Vaccination Reduces Health Care Utilization and Costs Among Older Adults
10/31/2025
Juliet Gallagher
A new retrospective cohort study using the Humana Healthcare Research database highlights the significant clinical and economic benefits of respiratory syncytial virus (RSV) vaccination among older adults in the US.
A new retrospective cohort study using the Humana Healthcare Research database highlights the significant clinical and economic benefits of respiratory syncytial virus (RSV) vaccination among older adults in the US.
A new retrospective cohort study...
10/31/2025
Pharmacy Learning Network
News
RSVpreF Vaccine Proves Highly Effective Against Severe RSV in Older Adults
10/29/2025
Grace Taylor, MS, MA
A real-world study led by Kaiser Permanente Southern California shows that Pfizer’s RSVpreF vaccine provides strong protection against severe respiratory syncytial virus (RSV)–related illness and hospitalizations in older adults, including...
A real-world study led by Kaiser Permanente Southern California shows that Pfizer’s RSVpreF vaccine provides strong protection against severe respiratory syncytial virus (RSV)–related illness and hospitalizations in older adults, including...
A real-world study led by Kaiser...
10/29/2025
Pharmacy Learning Network
News
RSV Poses Sixfold Higher Hospitalization and Death Risk for Long-Term Care Residents
10/21/2025
Lisa Kuhns, PhD, MD
Older adults living in long-term care facilities face a dramatically higher risk of severe illness and death from respiratory syncytial virus (RSV) than their community-dwelling peers, according to new data published in The Journal of the...
Older adults living in long-term care facilities face a dramatically higher risk of severe illness and death from respiratory syncytial virus (RSV) than their community-dwelling peers, according to new data published in The Journal of the...
Older adults living in long-term...
10/21/2025
Pharmacy Learning Network
News
RSV Vaccines Cut Hospitalizations in Older Adults but Show Gaps in High-Risk Groups
09/29/2025
Grace Taylor, MS, MA
A new 2-season study finds respiratory syncytial virus (RSV) vaccines significantly reduce hospitalizations in adults 60 and older, though protection wanes over time and is weaker in immunocompromised patients and those with cardiovascular...
A new 2-season study finds respiratory syncytial virus (RSV) vaccines significantly reduce hospitalizations in adults 60 and older, though protection wanes over time and is weaker in immunocompromised patients and those with cardiovascular...
A new 2-season study finds...
09/29/2025
Pharmacy Learning Network
News
RSV Pneumonia Leads to Elevated ICU Admissions and Mortality in Older Adults
08/08/2025
Grace Taylor, MS, MA
Respiratory syncytial virus (RSV) pneumonia leads to high intensive care unit (ICU) admission and mortality rates in older adults, rivaling those of influenza and human metapneumovirus, according to a study published in the Journal of...
Respiratory syncytial virus (RSV) pneumonia leads to high intensive care unit (ICU) admission and mortality rates in older adults, rivaling those of influenza and human metapneumovirus, according to a study published in the Journal of...
Respiratory syncytial virus...
08/08/2025
Pharmacy Learning Network
News
Dorzolamide and Timolol Ophthalmic Solution Recalled Due to Defective Containers
08/06/2026
Rebecca Amrick
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate...
08/06/2026
Pharmacy Learning Network
News
Azelaic Acid Gel Recalled Due to CGMP Deviations
08/06/2026
Rebecca Amrick
A voluntary Class II recall has been issued for azelaic acid gel due to Current Good Manufacturing Practice (CGMP) deviations, resulting from the product’s abnormal texture.
A voluntary Class II recall has been issued for azelaic acid gel due to Current Good Manufacturing Practice (CGMP) deviations, resulting from the product’s abnormal texture.
A voluntary Class II recall has...
08/06/2026
Pharmacy Learning Network
News
Mycophenolate Mofetil Recalled Due to the Presence of Precipitate
08/06/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for mycophenolate mofetil due to the presence of precipitate, affecting 5688 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for mycophenolate mofetil due to the presence of precipitate, affecting 5688 vials.
The US Food and Drug...
08/06/2026
Pharmacy Learning Network
PharmLaw
Arkansas Suspends Enforcement of Specialty Drug Distribution Law Following Constitutional Challenge
08/05/2026
Hannah Musick
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of...
08/05/2026
Pharmacy Learning Network
News
Lidocaine Hydrochloride Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has...
07/30/2026
Pharmacy Learning Network
News
Glycopyrrolate Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are...
07/30/2026
Pharmacy Learning Network
News
Amlodipine and Olmesartan Medoxomil Tablets Recalled Due to Failed Dissolution Specifications
07/30/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug...
07/30/2026
Pharmacy Learning Network
PharmLaw
EyePoint Pharmaceuticals Agrees to $4.6 Million False Claims Act Settlement
07/29/2026
Grace Taylor, MS, MA
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has...
07/29/2026
Pharmacy Learning Network
News
CareOne Carbamide Peroxide Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Cleviprex Recalled Due to Lack of Sterility Assurance
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use